Distinctive structure of viruses and their complicated life cycle have made the discovery of definite treatments against antiviral infections extremely demanding. Therefore, the scientific society has to be ready to respond with adequately and sufficient tools and knowledge. These include efforts to strengthen disease-specific systems and capacities, including pharmaceuticals and other public health non-drug interventions. The world has bet most of its research funding on finding a vaccine and effective drugs. That effort is vital, but it must be accompanied by research on how to target and improve the non-drug interventions that are the only available tools that can be used to protect us against pandemics, while we wait again for new vaccine or drug (Holmes et al., 2017). As we are still unable to predict with every confidence the progress of coronavirus pandemic and considering that the next pandemic is most likely to be caused by influenza, the discovery of antiviral compounds continues to be the priority public health threat in the world (Mani et al., 2020; Martinez et al., 2020). Most important, we need to have a range of available antiviral tools that can be responding rapidly and effectively to emergencies. For practical application, non-drug antiviral compounds must be available in massive amounts, and must be produced cost-effectively.
